Drug intelligence / Profile preview

SOBI006

Development stage: Unknown
Lead developer: Sobi

Overview

**SOBI006** is a preclinical anti-interleukin-1 biologic discovered and developed by Sobi. Available public information identifies it only as an IL-1 antagonist program, with no disclosed international nonproprietary name, molecular format, route, dosage form, or disease-specific indication. The asset appears to have remained in early research and was reported by Sobi in 2019 as part of a planned divestment of non-core preclinical programs during a strategic shift toward later-stage hematology and immunology development.

Targets

IL1A (Interleukin 1 alpha)

Beyond the preview

Go deeper on SOBI006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOBI006.

Explore the full profile